Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:
“Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC
47.7% patients had investigator-assessed visceral crisis
R+ET vs ChT
mPFS -> 21.8 vs 12.8 mo
ORR -> 66.1% vs 61.8%.”
Proceed to the article.
Source: Yakup Ergün/X
.